Literature DB >> 11436113

Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation.

N Fujii1, K Takenaka, K Shinagawa, K Ikeda, Y Maeda, K Sunami, Y Hiramatsu, K Matsuo, F Ishimaru, K Niiya, T Yoshino, N Hirabayashi, M Harada.   

Abstract

Hepatic graft-versus-host disease (GVHD) generally presents as cholestatic jaundice, and increased serum alkaline phosphatase (ALP) is followed by hyperbilirubinemia and clinical jaundice. Currently accepted standards for evaluating the clinical severity of GVHD are based not on serum aminotransferase levels but on the serum bilirubin level. We describe a 17-year-old Japanese female who had increased aminotransferases without cholestasis on day 23 after allogeneic peripheral blood stem cell transplantation (allo-PBSCT). Liver biopsy revealed lymphocytic infiltration of the portal tracts and pericentral necrosis of the lobuli. The limiting plates were not clearly defined due to cellular infiltrates. There was periductal lymphocytic infiltration and vacuolization of the biliary epithelial cells with exocytosis, compatible with GVHD of cholangiohepatitic type. These findings indicate that acute hepatic GVHD may present as acute hepatitis and this should be included in the differential diagnosis for patients with increased aminotransferases after allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11436113     DOI: 10.1038/sj.bmt.1702997

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  A flare-up of chronic graft-versus-host disease of the liver that mimics acute hepatitis in a recipient of an allogeneic peripheral blood stem cell transplant.

Authors:  Takehiko Mori; Akihiro Yokoyama; Yoshinobu Aisa; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

2.  Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.

Authors:  Rohtesh S Mehta; Antonio Di Stasi; Chitra Hosing; Nina Shah; Katayoun Rezvani; Amin Alousi; Susan O'Brien; William Wierda; Michael Keating; Elizabeth J Shpall
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-27

Review 3.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

4.  Chronic graft-versus-host disease of the liver presenting as an acute hepatitis following nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Hoyoung Maeng; Jae-Hyun Lee; June Won Cheong; Seung Tae Lee; Jee Sook Hahn; Yun Woong Ko; Yoo Hong Min
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

5.  Development of a novel histologic diagnostic algorithm for hepatic graft-versus-host disease.

Authors:  Ashley E Stueck; Thomas D Schiano; M Isabel Fiel
Journal:  Mod Pathol       Date:  2017-12-01       Impact factor: 7.842

Review 6.  Stem cells in clinical practice: applications and warnings.

Authors:  Daniele Lodi; Tommaso Iannitti; Beniamino Palmieri
Journal:  J Exp Clin Cancer Res       Date:  2011-01-17

7.  Consensus on the histopathological evaluation of liver biopsies from patients following allogeneic hematopoietic cell transplantation.

Authors:  Judith Stift; Hideo A Baba; Elisabeth Huber; Birgit Federmann; Hans-Peter Fischer; Annette Schmitt-Graeff; Herrad Baurmann; Wolfgang Bethge; Peter Schirmacher; Fritz Wrba; Hildegard Greinix; Falko Fend; Rainer Schwerdtfeger; Howard M Shulman; Daniel Wolff; Thomas Longerich
Journal:  Virchows Arch       Date:  2014-01-03       Impact factor: 4.535

8.  Nanocomposite treatment reduces disease and lethality in a murine model of acute graft-versus-host disease and preserves anti-tumor effects.

Authors:  Priscila T T Bernardes; Bárbara M Rezende; Carolina B Resende; Talles P De Paula; Alesandra C Reis; William A Gonçalves; Elias G Vieira; Maurício V B Pinheiro; Danielle G Souza; Marina G M Castor; Mauro M Teixeira; Vanessa Pinho
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.